HC Wainwright Reiterates Buy Rating for Compass Therapeutics (NASDAQ:CMPX)

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 458.66% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the stock. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Monday, September 16th. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a research note on Wednesday, August 7th.

Compass Therapeutics Stock Performance

CMPX stock opened at $1.79 on Monday. The firm has a 50 day moving average price of $1.74 and a 200-day moving average price of $1.41. Compass Therapeutics has a 52-week low of $0.77 and a 52-week high of $2.34. The firm has a market capitalization of $246.28 million, a price-to-earnings ratio of -5.14 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). The company had revenue of $0.85 million for the quarter. As a group, sell-side analysts forecast that Compass Therapeutics will post -0.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Bleakley Financial Group LLC purchased a new position in Compass Therapeutics in the 1st quarter worth about $80,000. Renaissance Technologies LLC raised its holdings in shares of Compass Therapeutics by 99.7% during the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after purchasing an additional 70,200 shares during the last quarter. Rhumbline Advisers lifted its position in Compass Therapeutics by 10.3% during the second quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after purchasing an additional 12,315 shares during the period. Vanguard Group Inc. lifted its position in Compass Therapeutics by 1.7% during the first quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock valued at $8,221,000 after purchasing an additional 71,008 shares during the period. Finally, Panagora Asset Management Inc. purchased a new stake in Compass Therapeutics in the second quarter worth approximately $68,000. 68.43% of the stock is owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.